PTN - Palatin Technologies, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

Palatin Technologies, Inc.

Cedar Brook Corporate Center
4B Cedar Brook Drive
Cranbury, NJ 08512
United States
609-495-2200
http://www.palatin.com

SectorHealthcare
IndustryDiagnostic Substances
Full Time Employees22

Key Executives

NameTitlePayExercisedAge
Dr. John K. A. Prendergast Ph.D.Co-Founder & Non-Exec. Chairman95kN/A63
Dr. Carl Spana Ph.D.Co-Founder, Pres, CEO & Director947.65kN/A55
Mr. Stephen T. Wills CPA, MSTCFO, COO, Principal Accounting Officer, executive VP, Treasurer & Sec.886.45kN/A60
Burns McClellanVP of Investor RelationsN/AN/AN/A
Dr. Johna Lucas M.A., M.D., F.A.C.O.G.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include melanocortin peptide system program, including PL-8177 is a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, is a preclinical development candidate for treating ocular inflammation. In addition, the company develops natriuretic peptide system programs, including PL­3994, a natriuretic peptide receptor-A agonist for treatment of cardiovascular indications; and PL-5028, s dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Corporate Governance

Palatin Technologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.